全球合同研究組織 (CRO) 市場:增長機會

隨著許多臨床研究在印度、印度尼西亞、中國、拉丁美洲、中東和南非等新興國家和第三世界國家/地區進行，該行業的動態正在發生顯著變化。 因此，一些本地 CRO 正在通過與更大的全球 CRO 合作以支持本地臨床研究來擴大其市場範圍。

此外，該行業越來越多地採用大規模分散式臨床試驗，在 2020-21 年和 2021-2022 年分別實現了 50% 和 28% 的同比增長。 這些變化增加了電子臨床解決方案供應商的進入，促進了與 CRO 和製藥公司的合作，以提供數據採集、藥物警戒和研究管理等前沿解決方案。

本報告考察了全球合同研究組織 (CRO) 市場，並提供了市場概況、影響市場增長的各種因素的分析、提供的服務和利益相關者、投資趨勢、收入預測、各個細分市場，我們編制了詳細分析區域、競爭分析、增長機會分析等。

內容

戰略要務

• 增長問題
• 戰略要務 8 (TM)
• 三大戰略要務的影響
• 增長機會推動增長PipelineEngine (TM)

增長機會分析

• 分析範圍
• 分類
• 外圍部門
• 市場趨勢分析
• 供應商生態系統
• 增長動力
• 抑制增長的因素

服務和利益相關者

• 服務和利益相關者
• CRDMO:外包的未來
• 支持藥物發現和開發的 CRDMO 交易

臨床研究的數字化和去中心化

• 藥物開發價值鏈的數字化
• 臨床研究數字化
• DCT:對 CRO 行業的未來影響

投資趨勢

• 投資趨勢:藥物開發的協作方法
• 早期到晚期 CRO 服務協作:非臨床
• 早期至晚期 CRO 服務合作:臨床
• 支持產業整合的技術合作夥伴關係
• 通過行業收購擴大 CRO 的專業知識

增長機會分析:CRO

• 增長指標
• 預測假設
• 收入預測
• 利潤預測:臨床/非臨床
• 收入預測分析

增長機會分析:非臨床 CRO

• 增長指標
• 盈利預測的假設和研究方法
• 主要服務:藥物發現和臨床前研究
• 藥物發現和臨床前開發的細微差別
• 醫藥研發費用
• 收入預測
• 收入預測:按非臨床開發階段
• 收入預測分析

增長機會分析:臨床

• 增長指標
• 收入預測假設
• 收入預測:研究方法
• 收入預測
• 收入預測:按臨床開發階段
• 利潤率預測:按臨床開發階段
• 收入預測分析
• 臨床研究:按治療領域分類

區域分析

• 按地區劃分的收入份額分析
• 北美:主要趨勢
• 北美:按臨床開發階段預測收入
• 北美:收入預測分析
• 歐洲:主要趨勢
• 歐洲:按臨床開發階段預測收入
• 歐洲:收入份額分析
• 亞太地區:主要趨勢
• 亞太地區:按臨床開發階段預測收入
• 亞太地區:收入份額分析
• 其他地區:主要趨勢
• 其他地區:按臨床開發階段預測收入
• 其他地區:收入份額分析

競爭評級

• 競爭環境
• 主要公司
• 收益分成
• 收益分成分析

臨床試驗費用及周邊服務評估

• 按服務類型細分的費用
• 外圍服務:分析測試服務
• 外圍服務:臨床結果和上市後監測
• 外圍服務:數據採集和管理

增長機會領域

• 增長機會 1:藥物發現和臨床前藥物測試的靈活合作模式
• 增長機會 2:生物製品定制測試解決方案的生物分析 CRO 合作夥伴關係
• 增長機會 3:藥物警戒服務的電子臨床解決方案
• 增長機會 4:AI 驅動的腫瘤學臨床試驗設計、招募和執行

下一步

Strong Competitive Intensity is Mandating a Greater Industry Convergence Resulting in a Strong Market Growth

The COVID-19 pandemic led to a sudden surge in R&D activities across the world. Both small and large pharmaceutical and biotech companies were engaged in tremendous efforts to either develop new molecules or repurpose existing therapies as potential drugs for COVID-19 treatment.

The trend is likely to continue with small-to-medium-segment and emerging biopharma participants introducing novel therapies across various indications, primarily oncology, infectious diseases, and neurology. Per Pharma Intelligence's annual R&D review, global non-clinical and clinical pipelines have grown by leaps and bounds--more than 10,000 molecules were in preclinical development and about 6,000 molecules were in clinical development as of January 2022.

Industry dynamics saw a huge shift with much of the clinical research being conducted in emerging economies and third-world countries, such as India, Indonesia, China, LATAM, the Middle East, and South Africa. As a result, several local CROs expanded their market reach by partnering with larger, global CROs and providing local clinical research support. The industry also moved to adopt large-scale decentralized clinical trials, with a year-over-year growth of 50% and 28% between 2020-2021 and 2021-2022, respectively. Such changes expanded the participation of eClinical solution vendors and encouraged collaborations with CROs and pharmaceutical companies, providing cutting-edge solutions for data capture, pharmacovigilance, trial management, and other applications.

Drug discovery and preclinical service outsourcing (traditionally conducted in house because of IP infringement issues) has increased, owing to the rise in specialized drug discovery and preclinical CROs and the CRDMO model gaining traction. CROs work as risk-sharing partners and offer one-stop-shop services to pharmaceutical companies, thereby cutting down costs and shortening the timeline of development.

Key Issues Addressed:

• What are the general industry trends pertaining to the global CRO industry?

• What are the key drivers triggering large-scale outsourcing of both early- and late-stage nonclinical and clinical development?

• What are the key emerging business models providing a competitive advantage to pharmaceutical sponsors and how is it supporting industry convergence?

• Who are the leading participants driving market growth?

• What is the opportunity for small- to medium-segment CRO participants in a sea of competitors?

• How is the application of technology supporting the growth of the CRO market and, in general, the drug development outsourcing services?

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Contract Research Organization (CRO) Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation
• Peripheral Segments
• Market Trend Analysis
• Market Trend Analysis (continued)
• Vendor Ecosystem
• Growth Drivers
• Growth Restraints

Services and Stakeholders

• Services and Stakeholders
• CRDMO-The Future of Outsourcing
• CRDMO-The Future of Outsourcing (continued)
• CRDMO Transactions to Support Drug Discovery and Development
• CRDMO Transactions to Support Drug Discovery and Development (continued)

Digitization and Decentralization of Clinical Research

• Digitization of the Drug Development Value Chain
• Digitization of Clinical Research
• DCTs-Future Impact on the CRO Industry

Investment Trends

• Investment Trends-Collaborative Approach for Drug Development
• Early- to Late-stage CRO Service Collaboration-Nonclinical
• Early- to Late-stage CRO Service Collaboration-Nonclinical (continued)
• Early- to Late-stage CRO Service Collaboration-Nonclinical (continued)
• Early- to Late-stage CRO Service Collaboration-Clinical
• Early- to Late-stage CRO Service Collaboration-Clinical (continued)
• Early- to Late-stage CRO Service Collaboration-Clinical (continued)
• Technology Partnerships Supporting Industry Convergence
• Technology Partnerships Supporting Industry Convergence (continued)
• Technology Partnerships Supporting Industry Convergence (continued)
• Expanding CRO Expertise through Industry Acquisitions
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)
• Expanding CRO Expertise through Industry Acquisitions (continued)

Growth Opportunity Analysis-CRO

• Growth Metrics
• Forecast Assumptions
• Forecast Assumptions (continued)
• Revenue Forecast
• Revenue Forecast-Clinical vs. Nonclinical
• Revenue Forecast Analysis
• Revenue Forecast Analysis (continued)

Growth Opportunity Analysis-Nonclinical CRO

• Growth Metrics
• Revenue Forecast Assumptions and Methodology
• Key Services-Drug Discovery and Preclinical Research,
• Nuances of Drug Discovery and Preclinical Development
• Pharmaceutical R&D Expenditure
• Revenue Forecast
• Revenue Forecast by Nonclinical Phases of Development
• Revenue Forecast Analysis
• Revenue Forecast Analysis (continued)
• Revenue Forecast Analysis (continued)

Growth Opportunity Analysis-Clinical

• Growth Metrics
• Revenue Forecast Assumptions
• Revenue Forecast Methodology
• Revenue Forecast
• Revenue Forecast by Clinical Phases of Development
• Percent Revenue Forecast by Clinical Phases of Development
• Revenue Forecast Analysis
• Revenue Forecast Analysis (continued)
• Clinical Trial Split by Therapy Area

Regional Analysis

• Revenue Share Analysis By Region
• North America-Key Trends
• North America-Revenue Forecast by Clinical Development Phase
• North America-Revenue Forecast Analysis
• Europe-Key Trends
• Europe-Revenue Forecast by Clinical Development Phase
• Europe-Revenue Share Analysis
• APAC-Key Trends
• APAC-Revenue Forecast by Clinical Development Phases
• APAC-Revenue Share Analysis
• RoW-Key Trends
• RoW-Revenue Forecast by Clinical Development Phase
• RoW-Revenue Share Analysis

Competitor Assessment

• Competitive Environment
• Key Competitors
• Revenue Share
• Revenue Share Analysis
• Revenue Share Analysis (continued)

Clinical Trial Costs and Peripheral Services Assessment

• Cost Split by Service Type
• Peripheral Services-Analytical Testing Services
• Peripheral Services-Clinical Outcomes and Post-market Surveillance
• Peripheral Services-Data Capture and Management

Growth Opportunity Universe

• Growth Opportunity 1: Agile Partnership Models for Drug Discovery and Preclinical Drug Testing
• Growth Opportunity 1: Agile Partnership Models for Drug Discovery and Preclinical Drug Testing (continued)
• Growth Opportunity 2: Bioanalytical CRO Partnerships for Customized Testing Solutions for Biologics
• Growth Opportunity 2: Bioanalytical CRO Partnerships for Customized Testing Solutions for Biologics (continued)
• Growth Opportunity 3: eClinical Solutions for Pharmacovigilance Services
• Growth Opportunity 3: eClinical Solutions for Pharmacovigilance Services (continued)
• Growth Opportunity 4: AI-enabled Oncology Trial Design, Recruitment, and Execution
• Growth Opportunity 4: AI-enabled Oncology Trial Design, Recruitment, and Execution (continued)

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• List of Exhibits (continued)
• Legal Disclaimer